Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Fabry Disease, Neuropathic Pain

In brief

The purpose of this study is to determine efficacy of gabapentin vs. placebo at controlling peripheral neuropathic pain in patients with Fabry disease, and reducing their use of opioid analgesics. The investigators are conducting a randomized, double-blind, placebo controlled, single center, cross-over study. The primary endpoint is percent reduction in patients' use of hydrocodone-acetaminophen.

Key facts

Study ID

NCT01588314

Run by

University of Minnesota

People needed

0

Starts

2012-04-01

Expected to finish

2014-06-01

Last updated by the study team

2019-05-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• diagnosis of Fabry Disease
• age ≥ 18 years of age at study enrollment
• current neuropathic pain at any severity level

You may not qualify if…

• known sensitivity or allergy to study drug
• history of illicit drug use
• pregnancy
• suicidal thoughts at study enrollment as assess by the C-SSRS

Where it is running

• University of Minnesota, Fariview — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.